The efficacy of antifibrinolytic therapy in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis

AIM: The efficacy of antifibrinolytics in subarachnoid hemorrhage remains unclear due to conflicting evidence from studies. MATERIALS & METHODS: Online databases were queried to include randomized controlled trials and propensity matched observational studies. We used Review Manager for the stat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fatima, Kaneez, Ur Rehman, Muhammad Aemaz, Asmar, Abyaz, Farooq, Hareem, Ahmad, Noor-Us-Sabah, Danial, Ahmad, Ur Rehman, Muhammad Ebaad, Khan, Abdullah Ali, Tahir, Sidra, Ahmed, Umair, Zubair, Salman, Khawaja, Ayaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2023
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203907/
https://www.ncbi.nlm.nih.gov/pubmed/37228855
http://dx.doi.org/10.2144/fsoa-2023-0014
Descripción
Sumario:AIM: The efficacy of antifibrinolytics in subarachnoid hemorrhage remains unclear due to conflicting evidence from studies. MATERIALS & METHODS: Online databases were queried to include randomized controlled trials and propensity matched observational studies. We used Review Manager for the statistical analysis, presenting results as odds ratios with 95% CI. RESULTS: The 12 shortlisted studies included 3359 patients, of which 1550 (46%) were in the intervention (tranexamic acid) group and 1809 (54%) in the control group. Antifibrinolytic therapy significantly reduced the risk of rebleeding (OR: 0.55; 95% CI: 0.40–0.75; p = 0.0002) with no significant decrease in poor clinical outcome (OR: 1.02; 95% CI: 0.86–1.20; p = 0.85) and all-cause mortality (OR: 0.92; CI: 0.72–1.17; p = 0.50). CONCLUSION: In patients with subarachnoid hemorrhage, antifibrinolytics reduce the risk of rebleeding without significantly affecting mortality or clinical outcomes.

Ejemplares similares